Class 3 Medicines Recall: Bristol-Myers Squibb Pharmaceuticals Limited, OPDIVO 10 mg/mL concentrate for solution for infusion (nivolumab), EL(24)A/11
Bristol-Myers Squibb Pharmaceuticals Limited has informed the MHRA that a potential product quality issue has been detected, relating to incomplete crimping of the metal crimp cap of OPDIVO 10mg/mL concentrate for solution for infusion (nivolumab) (1VLX10ML).
MDR number
MDR 181-03/24
Company name
Bristol-Myers Squibb Pharmaceuticals Limited
Product name
OPDIVO 10 mg/mL concentrate for solution for infusion (nivolumab), PLGB 15105/0133
SNOMED Code
29887611000001103
| Batch Number | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| 8053520 | 31/12/2025 | 1 | 10/11/2023 |
Active Pharmaceutical Ingredient: nivolumab
Brief description of the problem
Bristol-Myers Squibb Pharmaceuticals Limited has informed the MHRA that a potential product quality issue has been detected, relating to incomplete crimping of the metal crimp cap of OPDIVO 10mg/mL concentrate for solution for infusion (nivolumab) (1VLX10ML). Four thousand (4,000) units of the concerned batch, specified in the above table, was distributed in Great Britain (GB) between 10 November 2023 - 5 December 2023. This defect has been reported in vials manufactured from the same bulk batch in another market, although no defects have been reported in the UK market.
Advice for healthcare professionals
Stop using the above batches immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process. No further action is required concerning product that has already been administered.
Advice for patients
No action is required by patients as this is a Pharmacy and Wholesaler level recall. This product is administered by healthcare professionals directly. If you have concerns about a medicine you may be using, please contact your healthcare professional.
Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.
Further information
For medical information enquiries please contact the Bristol Myers Squibb Medical Information Department by phone (0800 731 1736) or email medical.information@bms.com.
Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
Yours faithfully
Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
Download document